Landscapes / Targets
GLP-1
A gut hormone released after meals. Drugs that copy it or switch on its receptor lower appetite and blood sugar.
50 drugs act on GLP-1, in 330 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs50
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
GIP + GLP-1 |
Eli Lilly · Public LLY |
Approved | Nov 2026soonPhase 3 trial completes | ||
| How it works | Copies two gut hormones | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 11 more | ||||
| Open drug page | |||||
GLP-1 receptor agonist |
Novo Nordisk · Public NVO |
Approved | 13 Dec 2026soonPhase 1 trial completes | ||
| How it works | Copies GLP-1 | ||||
| Next date | 13 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Obesity | ||||
| Open drug page | |||||
GLP-1 + glucagon |
Eli Lilly +1 · Public LLY · 1801.HK |
Approved in China | 31 Dec 2026Phase 3 trial completes | ||
| How it works | Copies two hormones | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 8 more | ||||
| Open drug page | |||||
GLP-1, cAMP-biased |
Sciwind Biosciences · Private |
Approved in China | 5 Jan 2027Phase 1/2 trial completes | ||
| How it works | Copies GLP-1 | ||||
| Next date | 5 Jan 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Obesity, Weight Management and 6 more | ||||
| Open drug page | |||||
Oral small-molecule GLP-1 |
Eli Lilly · Public LLY |
Approved | Feb 2027Phase 3 trial completes | ||
| How it works | A pill that switches on the GLP-1 receptor | ||||
| Next date | Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Overweight, Obesity and 26 more | ||||
| Open drug page | |||||
GLP-1 |
Novo Nordisk · Public NVO |
Approved | 1 Mar 2027Phase 3 trial completes | ||
| How it works | Copies GLP-1 | ||||
| Next date | 1 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 7 more | ||||
| Open drug page | |||||
— |
Hanmi Pharmaceutical Company Limited +1 · Public SNY |
Approved in South Korea | Nov 2027Phase 3 trial completes | ||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Type 2 diabetes | ||||
| Open drug page | |||||
GLP-1 receptor agonist |
Eli Lilly · Public LLY |
Approved | Dec 2027Phase 3 trial completes | ||
| How it works | Copies GLP-1 | ||||
| Next date | Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Type 2 diabetes | ||||
| Open drug page | |||||
Amylin + GLP-1 |
Novo Nordisk · Public NVO |
Filed | Dec 2026US FDA decision expected in Q4 2026 (company guidance, exact date not public) | ||
| How it works | Copies two hormones released after meals | ||||
| Next date | Dec 2026 · US FDA decision expected in Q4 2026 (company guidance, exact date not public) · press release | ||||
| Also tested for | Obesity, Type 2 diabetes and 1 more | ||||
| Open drug page | |||||
Oral small-molecule GLP-1 |
Hengrui +1 · Public 600276.SS · KLRA |
Filed in China | Dec 2026Phase 2 trial completes | ||
| How it works | A pill that switches on the GLP-1 receptor | ||||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity, Obesity and 3 more | ||||
| Open drug page | |||||
GLP-1 + GIP |
Hengrui +1 · Public 600276.SS · KLRA |
Filed in China | Dec 2026Phase 3 trial completes | ||
| How it works | Copies two gut hormones | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Type 2 diabetes and 17 more | ||||
| Open drug page | |||||
GIP + GLP-1 + glucagon |
Eli Lilly · Public LLY |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| How it works | Copies three hormones at once | ||||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 7 more | ||||
| Open drug page | |||||
GLP-1 + GIP unconfirmed |
Phase 3 | 1 Dec 2026soonPhase 3 trial completes | |||
| How it works | Copies two gut hormones | ||||
| Next date | 1 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Type 2 diabetes and 1 more | ||||
| Open drug page | |||||
GLP-1 + GIP + glucagon unconfirmed |
United Laboratories +1 · Public 3933.HK · NVO |
Phase 3 | 14 Jan 2027Phase 2 trial completes | ||
| How it works | Copies three hormones at once | ||||
| Next date | 14 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Obesity, Overweight and 9 more | ||||
| Open drug page | |||||
GLP-1 agonist + GIPR antagonist antibody |
Amgen · Public AMGN |
Phase 3 | 21 Jan 2027Phase 3 trial completes | ||
| How it works | Copies GLP-1 | ||||
| Next date | 21 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight and 10 more | ||||
| Open drug page | |||||
GLP-1 + GIP unconfirmed |
Huadong Medicine · Public 000963.SZ |
Phase 3 | 4 Feb 2027Phase 2 trial completes | ||
| How it works | Copies two gut hormones | ||||
| Next date | 4 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Obesity, Type 2 diabetes and 5 more | ||||
| Open drug page | |||||
Tirzepatidenot checked |
Glucose-dependent insulinotropic polypeptide receptor Agonist; GLP-1 receptor agonist |
Phase 3 | 14 Feb 2027Phase 3 trial completes | ||
| How it works | Copies GLP-1 | ||||
| Next date | 14 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | ||||
| Open drug page | |||||
Oral small-molecule GLP-1 unconfirmed |
Huadong Medicine · Public 000963.SZ |
Phase 3 | 16 Feb 2027Phase 3 trial completes | ||
| How it works | A pill that switches on the GLP-1 receptor | ||||
| Next date | 16 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Type 2 diabetes, Overweight and Obesity and 2 more | ||||
| Open drug page | |||||
GLP-1 + GIP unconfirmed |
Phase 3 | 28 Feb 2027Phase 2 trial completes | |||
| How it works | Copies two gut hormones | ||||
| Next date | 28 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Type 2 Diabetes (T2DM), Overweight or Obese Participants Without Diabetes | ||||
| Open drug page | |||||
GIP/GLP-1 receptor dual agonist |
Eli Lilly · Public LLY |
Phase 3 | Feb 2027Phase 2 trial completes | ||
| How it works | Copies two gut hormones | ||||
| Next date | Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Overweight, Obesity and 13 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 47 of 50 drugs. The other 3 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Description
- From Wikipedia: Glucagon-like peptide-1
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026